ASBP — Q2 2026 Financial Report Analysis

Q2 2026: a $63,000-revenue supplement maker raised $18 million, then agreed to buy a $30 million auto-parts business

Aspire Biopharma (renamed Aspire-Lakewood Holdings on September 8, 2026) is a former SPAC that went public in February 2025 by merging with a small company developing under-the-tongue ("sublingual") versions of aspirin and caffeine. In the quarter to June 30, 2026 it sold $63,104 of its Buzz Bomb caffeine product, spent $2.65 million running the business, and reported a net loss of $1.27 million, smaller than a year ago only because of a one-off $1.35 million accounting gain. The bigger news sits after the quarter: in August the company closed, by its own account, the purchase of Dura Automotive's Driver Control Systems (DCS) unit, an automotive supplier, for a $30 million headline price, more than twice its entire June 30 balance sheet. The Q2 numbers below describe a business that has since been reshaped.

At a glance

• Revenue $63,104 (Q2), $91,457 for the half. Sales only began in Q3 2025, so there is no year-ago comparison; Q2 was roughly 2.2x Q1's $28,353, but still tiny against costs.
• Sales and marketing $1.22 million vs $51,311 a year ago. The filing attributes the jump to "investor awareness costs and product sampling" — so a large part is promoting the stock, not just the product. That is about $19 of sales and marketing for every $1 of revenue.
• Cash $12.17 million at June 30, up from $1.00 million in December, almost all from $17.95 million of Series A convertible preferred stock sold in February and April. Shares outstanding rose about 11x in six months (117,780 to 1,295,234), even after two reverse splits (1-for-40 in January, 1-for-30 in May).

n/m = not meaningful: a percentage change on a loss, or from a zero base, doesn't tell you anything useful. Per-share figures are restated for both 2026 reverse splits. Source: Form 10-Q for the quarter ended June 30, 2026.

Takeaway: Read the Q2 net loss as a $2.62 million loss, not $1.27 million: the improvement versus last year comes entirely from writing off a $1.35 million liability after a lawsuit was dismissed, while the loss from actually running the business more than tripled. The company is now trading a fragile consumer-supplement start-up for a debt-financed auto-parts acquisition whose numbers have not yet been published, so the Q2 figures say little about what shareholders now own.

What drove the quarter

Operating costs tripled. Total operating expenses rose to $2.65 million from $0.80 million. By line:

• Sales and marketing: $1,215,025 vs $51,311. The 10-Q says the increase "reflects increases in marketing such as investor awareness costs and product sampling." Investor-awareness spending is money spent promoting a company to potential shareholders; the filing does not split it from product marketing.
• General and administrative: $970,211 vs $395,692, mainly higher legal and accounting fees. That includes $157,500 of stock-based pay (pay in shares rather than cash).
• Merger and acquisition costs: $229,418, all tied to the DCS deal.
• Research and development fell to $233,482 from $352,887, which management explains as lower product-development costs "as our products are now marketable."

The product barely covers its own cost. Q2 revenue of $63,104 against $50,818 of cost of goods leaves a gross margin (sales minus the direct cost of the product) of about 19%, before a $42,372 write-off of obsolete inventory pushed gross profit below zero.

Below the operating line, a one-off gain. "Gain on extinguishment of debt" of $1,353,679 came from writing off balances tied to a lawsuit by Srirama Associates, the SPAC's former sponsor, which had sued for a $1 million "promissory note fee." The Delaware Superior Court dismissed the claim with prejudice (meaning it cannot be refiled) on June 29, 2026. The two balance-sheet items that disappeared — the $1,000,000 note fee and $353,679 "due to affiliate" — add up exactly to the gain. Interest expense fell to zero in Q2 because the convertible notes and loans that carried it in 2025 were repaid or converted into shares.

What the headline numbers hide

• The "smaller loss" is an accounting gain, not progress. Excluding the $1.35 million lawsuit write-off, which brought in no cash, the Q2 net loss would have been about $2.62 million, larger than last year's $1.98 million. The operating loss grew to $2.68 million from $0.80 million.
• Cash burn is running ahead of the income statement. For the first half, operating activities used $5.15 million of cash against a net loss of $4.49 million. The gap comes mostly from a $0.95 million rise in prepaid expenses, while the reported loss was flattered by the non-cash gain above. Interest expense for the half ($1.60 million) was almost entirely non-cash write-off of debt discount ($1.58 million) booked in Q1.
• The per-share figures mean very little. The loss per share fell to $1.22 from $48.19, but that is because the weighted share count rose about 25x (to 1,037,874 from 41,111), not because the loss shrank by that much. Both 2026 reverse splits are already restated into these numbers.
• More dilution is lined up. At June 30 there were 17,050 Series A convertible preferred shares outstanding. In July, holders converted 850 of them at $7.92 a share into 107,323 common shares. At that same rate (our estimate — the price could change), the remaining ~16,200 preferred would turn into roughly 2 million common shares, more than the 1.3 million outstanding at June 30. On top of that come $3.75 million of convertible notes issued in August (convertible at $8.00) and an equity line that lets the company sell up to $100 million of stock over 24 months.
• Controls and auditor. Management concluded disclosure controls were "not effective," including around complex accounting areas. On September 24, 2026 the company dismissed its auditor, Turner Stone & Company. The related 8-K says there were no disagreements, and notes that Turner's report on the 2025 accounts included a going-concern paragraph — wording auditors use when they doubt a company can keep funding itself for another year. Management now says June 30 cash is enough for at least a year, but that assessment came before the full cost of the DCS deal is visible.

The DCS acquisition changes the company

Under a June 10, 2026 purchase agreement with FireFish TopCo, Aspire agreed to buy Dura Automotive's Driver Control Systems business — the filing describes it as a tier-one supplier of electronic driver-control systems for vehicles (tier-one suppliers sell directly to carmakers) — for $30 million plus $0.8 million for deferred revenue, less the business's debt and tax liabilities. Key terms from the 10-Q:

• Financing: a May 2026 commitment letter for a senior secured five-year term loan of up to $22.5 million at one-month SOFR (a benchmark lending rate) plus 3.25%. It was still subject to final documents in the 10-Q. A $3.75 million convertible note sold for $3.0 million (a 20% discount to face value) adds working capital. The closing agreement made release of the deal documents conditional on Aspire paying the price from its debt financing. Management's discussion says the acquisition was completed on August 10, 2026.
• Lakewood Capital's cut: a $500,000 closing fee, up to $200,000 of expenses, an annual management fee of 5% of adjusted EBITDA (earnings before interest, tax, depreciation and amortization) capped at $1 million, and 15% of DCS's equity (valued at about $4.5 million), vesting over two years. After year two, Lakewood can sell up to 5% of DCS a year back to the company at a 15% discount to an EBITDA-based valuation, paid in cash or stock.
• No numbers yet: the company says the purchase accounting was incomplete when the 10-Q was filed, and no DCS revenue or profit figures are given in it. The name change to Aspire-Lakewood followed in September.

For the biopharma side, the 10-Q says a successful bioavailability trial (a small study measuring how fast and how much of a drug reaches the blood) of sublingual high-dose aspirin finished in Q3 2025. It plans to file for FDA approval through the shortcut 505(b)(2) route, which leans on existing data for a known drug, in the first half of 2027, after one more clinical trial. In another passage the filing gives "late 2026 or early 2027," so the timing is not firm.

Outlook

The company gives no revenue or earnings guidance. What to watch in the Q3 10-Q, due around mid-November 2026:

1. Whether DCS is consolidated, and on what terms. That means the final purchase price, how much was borrowed, the interest cost, and DCS's revenue and profit. Those figures will decide whether this is now an auto-parts company with a small supplement side business, and whether the debt can be serviced from DCS's cash flow.
2. Cash after closing. June 30 cash of $12.17 million plus the $3.0 million note proceeds, set against roughly $0.86 million a month of first-half operating cash burn and the cash part of a $30 million deal.
3. Dilution. Further preferred conversions and any use of the $100 million equity line.

Our read: this is a speculative micro-cap whose existing business is pre-scale (under $100,000 of revenue in six months) and whose value now depends on an acquired business that has not reported a single figure in a public filing. Until the Q3 report shows DCS's numbers, the risk lies in financing and execution far more than in the aspirin and caffeine products.